Billie Vincent
Adult Health · Bethalto, ILNPI 1639508039
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 394 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 27.5% of the total. Reporting peaked in 2021 at $2,361 and has fallen 67.6% since, to $764 in 2025. Among adult health clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 394 payments — averaging $15.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$1K
- Lilly USA, LLC$936
- AstraZeneca$288
- Merck$255
- Takeda Pharmaceuticals U.S.A., Inc.$182
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,972100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 115 | $1,645 |
| Novo Nordisk | 69 | $1,039 |
| Lilly USA, LLC | 53 | $936 |
| AstraZeneca | 19 | $288 |
| Merck | 17 | $255 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $182 |
| Biohaven Pharmaceuticals, Inc. | 22 | $175 |
| Eisai Inc. | 8 | $146 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $137 |
| Abbott | 7 | $135 |
| Boehringer Ingelheim | 5 | $94 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $88 |
| Amarin Pharma, Inc. | 5 | $87 |
| Exact Sciences | 5 | $86 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $65 |
| Sanofi-aventis U.S. LLC | 4 | $61 |
| Kowa Pharmaceuticals America, Inc. | 3 | $61 |
| GSK | 4 | $59 |
| Otsuka America Pharmaceutical, Inc. | 4 | $54 |
| Amgen | 3 | $53 |
| Ironwood Pharmaceuticals, Inc | 3 | $48 |
| Exeltis, USA Inc. | 3 | $44 |
| Sunovion Pharmaceuticals Inc. | 2 | $44 |
| Novartis | 3 | $43 |
| Pfizer | 3 | $42 |
| Adlon Therapeutics L.p. | 2 | $36 |
| Antares Pharma, Inc. | 1 | $17 |
| Nevro Corp. | 1 | $17 |
| Bayer | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Upsher-smith Laboratories LLC | 1 | $14 |
How this compares
$5,984 in reported general payments places this provider in the 90th percentile of 553 adult health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 63 | $70,076 |
| JardianceEmpagliflozin | 47 | $48,696 |
| OzempicSemaglutide | 27 | $33,547 |
| EliquisApixaban | 24 | $32,343 |
| TrulicityDulaglutide | 21 | $27,717 |
| EntrestoSacubitril/Valsartan | 17 | $11,543 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $7,233 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $6,837 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,705 |
| Arnuity ElliptaFluticasone Furoate | 12 | $3,338 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 127 | $2,688 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $2,240 |
| Omeprazole | 104 | $2,169 |
| Atorvastatin Calcium | 151 | $1,816 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $1,664 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $936 | $97,79384 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $94 | $54,40158 claims |
| Novo NordiskOzempic | $1,039 | $33,54727 claims |
| PfizerEliquis | $42 | $32,34324 claims |
| NovartisEntresto | $43 | $11,54317 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $61 | $7,23314 claims |
| GSKArnuity Ellipta | $59 | $3,33812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 553 adult health providers in Illinois.
Other adult health in Bethalto
- Kimberly KearnsHoffman Estates$531K
- Leslie ForresterArlington Heights$97K
- Colleen FolkersChicago$86K
- Matthew BurkeChicago$44K
- Jacklyn GideonChicago$38K
- Jennifer GreenfieldChicago$35K
- Tammy PomaChicago$32K
- Tammy BrownNorth Chicago$31K
- Eileen SchedelAurora$21K
- Julia BuesserGurnee$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.